TY  - JOUR
A1  - Marre, R.
A1  - Hacker, Jörg
A1  - Braun, V.
T1  - The cell-bound hemolysin of Serratia marcescens contributes to uropathogenicity
N2  - No abstract available
KW  - Infektionsbiologie
KW  - Serratia marcescens
KW  - uropathogenicity
KW  - hemolysin
KW  - rat
Y1  - 1989
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-59576
ER  - 
TY  - JOUR
A1  - Balkenhol, Johannes
A1  - Kaltdorf, Kristin V.
A1  - Mammadova-Bach, Elmina
A1  - Braun, Attila
A1  - Nieswandt, Bernhard
A1  - Dittrich, Marcus
A1  - Dandekar, Thomas
T1  - Comparison of the central human and mouse platelet signaling cascade by systems biological analysis
JF  - BMC Genomics
N2  - Background 
Understanding the molecular mechanisms of platelet activation and aggregation is of high interest for basic and clinical hemostasis and thrombosis research. The central platelet protein interaction network is involved in major responses to exogenous factors. This is defined by systemsbiological pathway analysis as the central regulating signaling cascade of platelets (CC). 

Results 
The CC is systematically compared here between mouse and human and major differences were found. Genetic differences were analysed comparing orthologous human and mouse genes. We next analyzed different expression levels of mRNAs. Considering 4 mouse and 7 human high-quality proteome data sets, we identified then those major mRNA expression differences (81%) which were supported by proteome data. CC is conserved regarding genetic completeness, but we observed major differences in mRNA and protein levels between both species. Looking at central interactors, human PLCB2, MMP9, BDNF, ITPR3 and SLC25A6 (always Entrez notation) show absence in all murine datasets. CC interactors GNG12, PRKCE and ADCY9 occur only in mice. Looking at the common proteins, TLN1, CALM3, PRKCB, APP, SOD2 and TIMP1 are higher abundant in human, whereas RASGRP2, ITGB2, MYL9, EIF4EBP1, ADAM17, ARRB2, CD9 and ZYX are higher abundant in mouse. Pivotal kinase SRC shows different regulation on mRNA and protein level as well as ADP receptor P2RY12. 

Conclusions 
Our results highlight species-specific differences in platelet signaling and points of specific fine-tuning in human platelets as well as murine-specific signaling differences.
KW  - interspecies comparison
KW  - transcriptome
KW  - proteome
KW  - platelet
KW  - network
KW  - signaling
KW  - mouse
KW  - human
KW  - interactome
KW  - cascade
Y1  - 2020
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-230377
VL  - 21
ER  - 
TY  - JOUR
A1  - Bolm, Louisa
A1  - Zemskov, Sergii
A1  - Zeller, Maria
A1  - Baba, Taisuke
A1  - Roldan, Jorge
A1  - Harrison, Jon M.
A1  - Petruch, Natalie
A1  - Sato, Hiroki
A1  - Petrova, Ekaterina
A1  - Lapshyn, Hryhoriy
A1  - Braun, Ruediger
A1  - Honselmann, Kim C.
A1  - Hummel, Richard
A1  - Dronov, Oleksii
A1  - Kirichenko, Alexander V.
A1  - Klinkhammer-Schalke, Monika
A1  - Kleihues-van Tol, Kees
A1  - Zeissig, Sylke R.
A1  - Rades, Dirk
A1  - Keck, Tobias
A1  - Fernandez-del Castillo, Carlos
A1  - Wellner, Ulrich F.
A1  - Wegner, Rodney E.
T1  - Concepts and outcomes of perioperative therapy in stage IA-III pancreatic cancer — a cross-validation of the National Cancer Database (NCDB) and the German Cancer Registry Group of the Society of German Tumor Centers (GCRG/ADT)
JF  - Cancers
N2  - (1) Background: The aim of this study is to assess perioperative therapy in stage IA-III pancreatic cancer cross-validating the German Cancer Registry Group of the Society of German Tumor Centers — Network for Care, Quality, and Research in Oncology, Berlin (GCRG/ADT) and the National Cancer Database (NCDB). (2) Methods: Patients with clinical stage IA-III PDAC undergoing surgery alone (OP), neoadjuvant therapy (TX) + surgery (neo + OP), surgery+adjuvantTX (OP + adj) and neoadjuvantTX + surgery + adjuvantTX (neo + OP + adj) were identified. Baseline characteristics, histopathological parameters, and overall survival (OS) were evaluated. (3) Results: 1392 patients from the GCRG/ADT and 29,081 patients from the NCDB were included. Patient selection and strategies of perioperative therapy remained consistent across the registries for stage IA-III pancreatic cancer. Combined neo + OP + adj was associated with prolonged OS as compared to neo + OP alone (17.8 m vs. 21.3 m, p = 0.012) across all stages in the GCRG/ADT registry. Similarly, OS with neo + OP + adj was improved as compared to neo + OP in the NCDB registry (26.4 m vs. 35.4 m, p < 0.001). (4) Conclusion: The cross-validation study demonstrated similar concepts and patient selection criteria of perioperative therapy across clinical stages of PDAC. Neoadjuvant therapy combined with adjuvant therapy is associated with improved overall survival as compared to either therapy alone.
KW  - pancreatic cancer
KW  - perioperative therapy
KW  - neoadjuvant therapy
KW  - pancreatic surgery
Y1  - 2022
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-262174
SN  - 2072-6694
VL  - 14
IS  - 4
ER  -